Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 7/20 | 0.39 |
| ▸ | ACHE | P22303 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968303 | 0.91 | ABCG2 (0.47) | PTPN1EGFRHDAC1HDAC2HDAC6 | |
| SCHEMBL3969907 | 0.89 | TP53 (0.46) | PTPN1EGFRHDAC1HDAC2HDAC6 | |
| SCHEMBL3974915 | 0.89 | TP53 (0.46) | PTPN1EGFRHDAC1HDAC2HDAC6 | |
| SCHEMBL499220 | 0.89 | TP53 (0.46) | PTPN1EGFRHDAC1HDAC2HDAC6 | |
| SCHEMBL3969868 | 0.89 | TP53 (0.46) | PTPN1EGFRHDAC1HDAC2HDAC6 | |
| SCHEMBL3970906 | 0.86 | KRAS (0.51) | PTPN1DPP4ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1778808 | 0.85 | CA1 (0.48) | PTPN1DPP4ALDH1A1LMNAMAPT | |
| SCHEMBL499277 | 0.85 | CA1 (0.48) | PTPN1DPP4ALDH1A1LMNAMAPT | |
| SCHEMBL3969812 | 0.84 | CAPN1 (0.45) | PTPN1DPP4KDM4ELMNAMAPT | |
| SCHEMBL498833 | 0.83 | MAPT (0.44) | KDM4EALDH1A1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | claimed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | claimed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | PTPN1 1161/4885EGFR 901/4885HDAC1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.